Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study.

@article{Araujo2012DasatinibCW,
  title={Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study.},
  author={John Charles Araujo and Paul Mathew and Andrew James Armstrong and Edward Louis Braud and Edwin M. Posadas and Mathew Lonberg and Gary E. Gallick and G{\'e}ralyn C. Trudel and Prashni Paliwal and Shruti Agrawal and Christopher J. Logothetis},
  journal={Cancer},
  year={2012},
  volume={118 1},
  pages={63-71}
}
BACKGROUND To determine the potential efficacy of targeting both the tumor and bone microenvironment in patients with castration-resistant prostate cancer (PC), the authors conducted a phase 1-2 trial combining docetaxel with dasatinib, an oral SRC inhibitor. METHODS In phase 1, 16 men received dasatinib 50 to 120 mg once daily and docetaxel 60 to 75 mg/m(2) every 21 days. In phase 2, 30 additional men received dasatinib 100 mg once daily/docetaxel 75 mg/m(2) every 21 days. Efficacy endpoints… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS
60 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 60 extracted citations

Similar Papers

Loading similar papers…